Cogent Biosciences, Inc.

COGT · Nasdaq · United States

Share price · COGT

$27.81-9.59 (-25.64%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.7M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when COGT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026-7.1%
  2. 10 Nov 2026-5.7%
  3. 6 Nov 2026+7.0%
  4. 11 Aug 2026-6.8%
  5. 4 Aug 2026+10.2%
  6. 1 Apr 2026-8.4%
  7. 23 Mar 2026+6.1%

Share of unusual movement by asset

For each asset, the share of COGT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
bezuclastinib
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—72%
Other company news (earnings, financing, releases naming no asset)—7%
Sessions with no dated event—20%

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
KITSmall molecule
Systemic MastocytosisGastrointestinal Stromal Tumor
Phase 1
ERBB2 (HER2), including genetic alterations and wild-type overexpressionSmall molecule
Non-Small Cell Lung Cancer
Phase 1
PI3Kα H1047R (mutant-selective inhibitor)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(9)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

30 November 2026FDA action datebezuclastinibPDUFA date for bezuclastinib in GIST
US, FDA · Cogent Biosciences, Inc. · Source ↗
30 December 2026FDA action datebezuclastinibPDUFA date for bezuclastinib in nonadvanced systemic mastocytosis
US, FDA · Cogent Biosciences, Inc. · Source ↗
29 June 2027FDA action datebezuclastinibPDUFA date for bezuclastinib in advanced systemic mastocytosis
US, FDA · Cogent Biosciences, Inc. · Source ↗

Recent

15 September 2026Filing acceptedbezuclastinibFDA accepts bezuclastinib NDA in advanced systemic mastocytosis
US, FDA · Cogent Biosciences, Inc. · Source ↗
30 June 2026Filing submittedbezuclastinibNDA submitted for bezuclastinib in AdvSM
US, FDA · Source ↗
28 May 2026Filing acceptedbezuclastinibFDA accepts bezuclastinib NDA in GIST (with sunitinib) and grants Priority Review
US, FDA · Cogent Biosciences, Inc. · Source ↗
28 May 2026Priority reviewbezuclastinibFDA grants Priority Review for bezuclastinib NDA in GIST
US, FDA · Source ↗
16 March 2026Filing acceptedbezuclastinibFDA accepts bezuclastinib NDA in nonadvanced systemic mastocytosis
US, FDA · Cogent Biosciences, Inc. · Source ↗
10 November 2025Topline resultbezuclastinibPEAK Phase 3 (NCT05208047) met its primary endpoint of PFS
Cogent Biosciences · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$75M$218M+ $574M short-term inv.$111M-$81M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$71M$182M+ $611M short-term inv.$96M-$77M operating cash flowreport ↗
2026-Q1—$75M$242M+ $625M short-term inv.$97M-$87M operating cash flowreport ↗
2025-Q3—$69M$126M+ $266M short-term inv.$81M-$64M operating cash flowreport ↗
2025-Q2—$62M$128M+ $110M short-term inv.$74M-$55M operating cash flowreport ↗
2025-Q1—$63M$126M+ $120M short-term inv.$72M-$67M operating cash flowreport ↗
2024-Q3—$64M$97M+ $238M short-term inv.$71M-$52M operating cash flowreport ↗
2024-Q2—$54M$88M+ $275M short-term inv.$59M-$43M operating cash flowreport ↗
2024-Q1—$53M$216M+ $220M short-term inv.$58M-$53M operating cash flowreport ↗
2023-Q3—$50M$87M+ $192M short-term inv.$55M-$38M operating cash flowreport ↗
2023-Q2—$39M$214M+ $115M short-term inv.$44M-$32M operating cash flowreport ↗
2023-Q1—$36M$162M+ $60M short-term inv.$39M-$40M operating cash flowreport ↗
2022-Q3—$30M$142M+ $149M short-term inv.$35M-$34M operating cash flowreport ↗
2022-Q2—$29M$327M$35M-$26M operating cash flowreport ↗
2022-Q1—$25M$192M$31M-$28M operating cash flowreport ↗
2021-Q3—$15M$204M$19M-$14M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$270M$312M+ $589M short-term inv.$82M-$264M operating cash flowreport ↗

For the full year 2025, Cogent Biosciences did not disclose revenue. Research and development expenses totaled $269.78M, up 16.0% YoY from $232.66M, while the company reported a net loss of $328.94M. It ended the year with cash, cash equivalents and marketable securities of $900.8M.

Cogent guided to cash sufficient to fund operations into 2028 and expects to launch bezuclastinib in the second half of 2026 pending FDA approval. The SUMMIT NDA for NonAdvSM was submitted in December 2025, the APEX NDA for AdvSM remains on track for the first half of 2026, and the PEAK NDA for second-line GIST is being completed under Real-Time Oncology Review by April 2026. The company also highlighted six SUMMIT abstracts accepted for the 2026 AAAAI meeting, positive topline results from the PEAK and APEX trials, and approximately $546.8M in net proceeds from concurrent public offerings completed in November 2025.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$233M$98M+ $189M short-term inv.$64M-$208M operating cash flowreport ↗
2023-FY—$174M$53M+ $212M short-term inv.$48M-$154M operating cash flowreport ↗
2022-FY—$122M$141M+ $119M short-term inv.$35M-$119M operating cash flowreport ↗
2021-FY—$56M$221M+ $0 short-term inv.$18M-$59M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 8 sales ($383.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-01Ferrante Karen Jean · directorAward / grant (derivative)759——Form 4
2026-08-27Morris Arlene · directorOption exercise41,927$5.64$236KForm 4
2026-08-27Morris Arlene · directorOption exercise3,583$2.52$9KForm 4
2026-08-27Morris Arlene · directorOpen-market sale42,349$37.09$1.6MForm 4
2026-08-27Morris Arlene · directorOpen-market sale3,161$37.54$119KForm 4
2026-08-27Morris Arlene · directorOption exercise (derivative)41,927——Form 4
2026-08-27Morris Arlene · directorOption exercise (derivative)3,583——Form 4
2026-07-01Ferrante Karen Jean · directorAward / grant (derivative)627——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 303 reporting institutions held 186.3M shares ($6.9B, 107.1% of shares outstanding).

#InstitutionSharesValue
1FMR LLC23,122,748$890.0M
2BlackRock, Inc.16,045,014$617.6M
3DEERFIELD MANAGEMENT COMPANY, L.P.9,043,903$348.1M
4VANGUARD PORTFOLIO MANAGEMENT LLC7,333,333$282.3M
5VANGUARD CAPITAL MANAGEMENT LLC6,894,959$265.4M
6JANUS HENDERSON GROUP PLC5,965,125$229.6M
7STATE STREET CORP5,663,543$218.0M
8Fairmount Funds Management LLC5,503,418$211.8M
9RTW INVESTMENTS, LP5,458,675$210.1M
10TCG Crossover Management, LLC4,946,894$190.4M
11GOLDMAN SACHS GROUP INC4,434,054$170.7M
12Kynam Capital Management, LP4,037,331$155.4M
13GEODE CAPITAL MANAGEMENT, LLC3,699,519$142.4M
14WELLINGTON MANAGEMENT GROUP LLP3,578,622$137.7M
15Commodore Capital LP2,888,007$111.2M